Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

1.

Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.

Ascher-Svanum H, Weiden P, Nyhuis AW, Faries DE, Stauffer V, Kollack-Walker S, Kinon BJ.

Clin Schizophr Relat Psychoses. 2014 Jul;8(2):84-90, 90A. doi: 10.3371/CSRP.ASWE.022213.

PMID:
23446198
[PubMed - in process]
2.

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trial.

Faries D, Ascher-Svanum H, Phillips G, Nyhuis AW, Sugihara T, Stauffer V, Kinon BJ.

BMC Med Res Methodol. 2012 Sep 13;12:142. doi: 10.1186/1471-2288-12-142.

PMID:
22974273
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians.

Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ, Hoffmann VP.

Patient Prefer Adherence. 2011;5:547-54. doi: 10.2147/PPA.S23255. Epub 2011 Nov 3.

PMID:
22114469
[PubMed]
Free PMC Article
4.

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.

Ascher-Svanum H, Zhao F, Detke HC, Nyhuis AW, Lawson AH, Stauffer VL, Montgomery W, Witte MM, McDonnell DP.

BMC Psychiatry. 2011 Sep 23;11:152. doi: 10.1186/1471-244X-11-152.

PMID:
21943257
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Predictors of switching antipsychotic medications in the treatment of schizophrenia.

Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ.

BMC Psychiatry. 2010 Sep 28;10:75. doi: 10.1186/1471-244X-10-75.

PMID:
20920179
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives.

Ascher-Svanum H, Nyhuis AW, Stauffer V, Kinon BJ, Faries DE, Phillips GA, Schuh K, Awad AG, Keefe R, Naber D.

Curr Med Res Opin. 2010 Oct;26(10):2403-10. doi: 10.1185/03007995.2010.515900.

PMID:
20812791
[PubMed - indexed for MEDLINE]
7.

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.

Ascher-Svanum H, Nyhuis AW, Faries DE, Ball DE, Kinon BJ.

BMC Psychiatry. 2010 Jan 28;10:11. doi: 10.1186/1471-244X-10-11.

PMID:
20109170
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.

Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ.

BMC Psychiatry. 2009 Sep 2;9:54. doi: 10.1186/1471-244X-9-54.

PMID:
19725969
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example.

Faries DE, Nyhuis AW, Ascher-Svanum H.

Cost Eff Resour Alloc. 2009 May 27;7:11. doi: 10.1186/1478-7547-7-11.

PMID:
19473545
[PubMed]
Free PMC Article
10.

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.

Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ.

Curr Med Res Opin. 2008 May;24(5):1399-405. doi: 10.1185/030079908X297385 . Epub 2008 Apr 7.

PMID:
18397549
[PubMed - indexed for MEDLINE]
11.

Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.

Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A.

Schizophr Bull. 2008 Nov;34(6):1163-71. Epub 2007 Dec 21.

PMID:
18156640
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.

Smelson DA, Tunis SL, Nyhuis AW, Faries DE, Kinon BJ, Ascher-Svanum H.

J Clin Psychopharmacol. 2006 Dec;26(6):666-7. No abstract available.

PMID:
17110828
[PubMed - indexed for MEDLINE]
13.

Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.

Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R.

Value Health. 2006 Mar-Apr;9(2):77-89.

PMID:
16626411
[PubMed - indexed for MEDLINE]
14.

Outcomes of American Lung Association-Indiana Lung Centers asthma program.

Summers KH, Zillich AJ, Nyhuis AW, Twigg HL 3rd.

Dis Manag. 2005 Oct;8(5):311-8.

PMID:
16212516
[PubMed - indexed for MEDLINE]
15.

Alterations in predicted growth rates of pediatric kidneys treated with extracorporeal shockwave lithotripsy.

Lifshitz DA, Lingeman JE, Zafar FS, Hollensbe DW, Nyhuis AW, Evan AP.

J Endourol. 1998 Oct;12(5):469-75.

PMID:
9847072
[PubMed - indexed for MEDLINE]
16.

The use of a break-even analysis: financial analysis of a fast-track program.

Saywell RM Jr, Cordell WH, Nyhuis AW, Giles BK, Culler SD, Woods JR, Chu DK, McKinzie JP, Rodman GH Jr.

Acad Emerg Med. 1995 Aug;2(8):739-45.

PMID:
7584755
[PubMed - indexed for MEDLINE]
17.

Community hospital and medical school cooperation in continuing medical education.

Jay SJ, Casebeer L, Woods JR, Nyhuis AW, O'Toole JB.

Acad Med. 1995 Feb;70(2):136-41.

PMID:
7865040
[PubMed - indexed for MEDLINE]
18.

Does anybody really know what time it is? Does anybody really care?

Cordell WH, Olinger ML, Kozak PA, Nyhuis AW.

Ann Emerg Med. 1994 May;23(5):1032-6.

PMID:
8185095
[PubMed - indexed for MEDLINE]
19.

Management of lower pole nephrolithiasis: a critical analysis.

Lingeman JE, Siegel YI, Steele B, Nyhuis AW, Woods JR.

J Urol. 1994 Mar;151(3):663-7.

PMID:
8308977
[PubMed - indexed for MEDLINE]
20.

Accuracy of bar codes versus handwriting for recording trauma resuscitation events.

Chua RV, Cordell WH, Ernsting KL, Bock HC, Nyhuis AW.

Ann Emerg Med. 1993 Oct;22(10):1545-50.

PMID:
8214833
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk